TWELVE-MONTH INTERIM ANALYSIS OF EFFICACY AND SAFETY OF GIVOSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR ACUTE HEPATIC PORPHYRIA, IN THE ENVISION OPEN LABEL EXTENSION
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-11-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137920303308 |
| _version_ | 1818995426079014912 |
|---|---|
| author | R. Marchi L. Duarte S. E B. M R. Dc S. P S. U A.P. P B. Dm E. Al K. S P. C P. Jd |
| author_facet | R. Marchi L. Duarte S. E B. M R. Dc S. P S. U A.P. P B. Dm E. Al K. S P. C P. Jd |
| author_sort | R. Marchi |
| collection | DOAJ |
| first_indexed | 2024-12-20T21:13:39Z |
| format | Article |
| id | doaj.art-3dd2ae98e2b8473db173f594ca10463e |
| institution | Directory Open Access Journal |
| issn | 2531-1379 |
| language | English |
| last_indexed | 2024-12-20T21:13:39Z |
| publishDate | 2020-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj.art-3dd2ae98e2b8473db173f594ca10463e2022-12-21T19:26:28ZengElsevierHematology, Transfusion and Cell Therapy2531-13792020-11-014227TWELVE-MONTH INTERIM ANALYSIS OF EFFICACY AND SAFETY OF GIVOSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR ACUTE HEPATIC PORPHYRIA, IN THE ENVISION OPEN LABEL EXTENSIONR. Marchi0L. Duarte1S. E2B. M3R. Dc4S. P5S. U6A.P. P7B. Dm8E. Al9K. S10P. C11P. Jd12Alnylam Brasil Farmacêutica Ltda, São Paulo, SP, BrazilAlnylam Brasil Farmacêutica Ltda, São Paulo, SP, BrazilPorphyria Centre Sweden, Centre for Inherited Metabolic Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, SwedenIcahn School of Medicine at Mt. Sinai, New York, United StatesKing's College Hospital, London, United KingdomKing's College Hospital, London, United KingdomKlinikum Chemnitz, Chemnitz, GermanyHospital Clinic Barcelona, Barcelona, SpainUniversity of California, San Francisco, United StatesAlnylam Brasil Farmacêutica Ltda, São Paulo, SP, BrazilUniversity of Washington, Seattle, United StatesUniversity of Utah, Salt Lake City, United StatesUniversity of Utah, Salt Lake City, United Stateshttp://www.sciencedirect.com/science/article/pii/S2531137920303308 |
| spellingShingle | R. Marchi L. Duarte S. E B. M R. Dc S. P S. U A.P. P B. Dm E. Al K. S P. C P. Jd TWELVE-MONTH INTERIM ANALYSIS OF EFFICACY AND SAFETY OF GIVOSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR ACUTE HEPATIC PORPHYRIA, IN THE ENVISION OPEN LABEL EXTENSION Hematology, Transfusion and Cell Therapy |
| title | TWELVE-MONTH INTERIM ANALYSIS OF EFFICACY AND SAFETY OF GIVOSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR ACUTE HEPATIC PORPHYRIA, IN THE ENVISION OPEN LABEL EXTENSION |
| title_full | TWELVE-MONTH INTERIM ANALYSIS OF EFFICACY AND SAFETY OF GIVOSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR ACUTE HEPATIC PORPHYRIA, IN THE ENVISION OPEN LABEL EXTENSION |
| title_fullStr | TWELVE-MONTH INTERIM ANALYSIS OF EFFICACY AND SAFETY OF GIVOSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR ACUTE HEPATIC PORPHYRIA, IN THE ENVISION OPEN LABEL EXTENSION |
| title_full_unstemmed | TWELVE-MONTH INTERIM ANALYSIS OF EFFICACY AND SAFETY OF GIVOSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR ACUTE HEPATIC PORPHYRIA, IN THE ENVISION OPEN LABEL EXTENSION |
| title_short | TWELVE-MONTH INTERIM ANALYSIS OF EFFICACY AND SAFETY OF GIVOSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR ACUTE HEPATIC PORPHYRIA, IN THE ENVISION OPEN LABEL EXTENSION |
| title_sort | twelve month interim analysis of efficacy and safety of givosiran an investigational rnai therapeutic for acute hepatic porphyria in the envision open label extension |
| url | http://www.sciencedirect.com/science/article/pii/S2531137920303308 |
| work_keys_str_mv | AT rmarchi twelvemonthinterimanalysisofefficacyandsafetyofgivosirananinvestigationalrnaitherapeuticforacutehepaticporphyriaintheenvisionopenlabelextension AT lduarte twelvemonthinterimanalysisofefficacyandsafetyofgivosirananinvestigationalrnaitherapeuticforacutehepaticporphyriaintheenvisionopenlabelextension AT se twelvemonthinterimanalysisofefficacyandsafetyofgivosirananinvestigationalrnaitherapeuticforacutehepaticporphyriaintheenvisionopenlabelextension AT bm twelvemonthinterimanalysisofefficacyandsafetyofgivosirananinvestigationalrnaitherapeuticforacutehepaticporphyriaintheenvisionopenlabelextension AT rdc twelvemonthinterimanalysisofefficacyandsafetyofgivosirananinvestigationalrnaitherapeuticforacutehepaticporphyriaintheenvisionopenlabelextension AT sp twelvemonthinterimanalysisofefficacyandsafetyofgivosirananinvestigationalrnaitherapeuticforacutehepaticporphyriaintheenvisionopenlabelextension AT su twelvemonthinterimanalysisofefficacyandsafetyofgivosirananinvestigationalrnaitherapeuticforacutehepaticporphyriaintheenvisionopenlabelextension AT app twelvemonthinterimanalysisofefficacyandsafetyofgivosirananinvestigationalrnaitherapeuticforacutehepaticporphyriaintheenvisionopenlabelextension AT bdm twelvemonthinterimanalysisofefficacyandsafetyofgivosirananinvestigationalrnaitherapeuticforacutehepaticporphyriaintheenvisionopenlabelextension AT eal twelvemonthinterimanalysisofefficacyandsafetyofgivosirananinvestigationalrnaitherapeuticforacutehepaticporphyriaintheenvisionopenlabelextension AT ks twelvemonthinterimanalysisofefficacyandsafetyofgivosirananinvestigationalrnaitherapeuticforacutehepaticporphyriaintheenvisionopenlabelextension AT pc twelvemonthinterimanalysisofefficacyandsafetyofgivosirananinvestigationalrnaitherapeuticforacutehepaticporphyriaintheenvisionopenlabelextension AT pjd twelvemonthinterimanalysisofefficacyandsafetyofgivosirananinvestigationalrnaitherapeuticforacutehepaticporphyriaintheenvisionopenlabelextension |